Comparison of 10 and 20 µg/Kg/day PD-Grastim in Stem Cell Mobilization in Patients with Hematologic Malignancies Candidate for Autologous Stem Cell Transplantation

Abstract

Introduction: Today, autologous peripheral blood stem cell transplantation is considered as a substitute procedure for Autologous bone marrow transplantation. Treatment with G-CSF mobilizes CD34+ HSCs from bone marrow into peripheral blood and could be used as a marker for hematopoietic stem cells mobilization and subsequent apheresis. Methods: In this study, 60 patients that had hematologic malignancies were randomly categorized into the two groups and were given PD-grastim (group A: 20 μg/kg/day and B: 10 μg/kg/day) to evaluate 10 and 20 μg/kg/day of PD-grastim in stem cell mobilization for autologous transplantation. Their CD34+ cell enumeration was carried out when leukocyte count was reached above 10000 cells/μl. Apheresis was also carried out when CD34+ count was reached above 16 cells/μl. Results: Results of the groups A and B were statistically analyzed and there was a meaningful statistical difference in gender, drug taking day numbers, apheresis numbers, hospitalization period and injected blood units. Based on the results, group A patients had lesser hospitalization period and apheresis number than group B. Conclusion: This indicates that utilization of PD-grastim at dose 20 μl/kg/day has better therapeutic effects on the patients with hematologic malignancies and could be considered as the major therapeutic regimen.